Statement of Changes in Beneficial Ownership (4)
March 16 2021 - 4:48PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
PETKANAS DEAN |
2. Issuer Name and Ticker or Trading Symbol
NEUROPATHIX, INC.
[
NPTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
(Last)
(First)
(Middle)
3805 OLD EASTON ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/12/2021 |
(Street)
DOYLESTOWN, PA 18902
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/12/2021 | | A(1) | | 692308 | A | $0.13 (1) | 22984029 | I | See Note (2) |
Common Stock | 3/12/2021 | | A(3) | | 192308 | A | $0.13 | 23594432 | I | See Note (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option | $0.13 | 3/12/2021 | | A | | 1450000 | | (4) | 3/11/2031 | Common Stock | 1450000 | $0 | 1450000 | D | |
Explanation of Responses: |
(1) | The reporting person agreed to accept 692,308 restricted shares of the issuers common stock in exchange for the discharge of an aggregate of $90,000 of accrued but unpaid monies payable by the issuer to the reporting person as a portion of his salary. The issuance was approved by the issuers board of directors on March 12, 2021. The price of the shares acquired by the reporting person is equal to the closing price of the Companys common stock on March 11, 2021, which was $0.13. |
(2) | Aggregate amount of shares beneficially owned by the reporting person includes shares held by him directly as well as indirectly through Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC. The reporting person disclaims beneficial ownership of the securities held by Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC, except to the extent of his pecuniary interest therein. |
(3) | Golden Gate Capital Partners, LLC agreed to accept 192,308 restricted shares of the issuer's common stock in exchange for the discharge of an aggregate of $25,000 of accrued but unpaid corporate expenses payable by the issuer to Golden Gate Capital Partners, LLC. The issuance was approved by the issuer's board of directors on March 12, 2021. The price of the shares acquired by Golden Gate Capital Partners, LLC is equal to the closing price of the Company's common stock on March 11, 2021, which was $0.13. |
(4) | 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
PETKANAS DEAN 3805 OLD EASTON ROAD DOYLESTOWN, PA 18902 | X |
| Chief Executive Officer |
|
Signatures
|
/s/ Dean Petkanas | | 3/16/2021 |
**Signature of Reporting Person | Date |
Neuropathix (CE) (USOTC:NPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuropathix (CE) (USOTC:NPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024